Business Wire

Finlight and LINKS Analytics announce a new partnership

Share

Finlight, an asset management software provider for family offices, today announced that it had partnered with LINKS Analytics, an innovative data-driven provider of stress testing and scenario analysis solutions to institutional investors, to broaden their offering around portfolio risk management.

Through this strategic partnership, Finlight and LINKS Analytics provide a robust tool for comparing scenarios and analysing how secular shifts such as climate change, ageing population, automation or pandemics, impact portfolios. The integrated solution will be available in September 2020 for pension funds, insurance companies and family offices, enabling a more holistic support of all their asset management needs.

“As someone who worked for pension fund allocators and family offices, I can confirm that both groups have more in common than many would think,” says JB Tanqueray, CEO and Co-Founder of Finlight. “They are long term investors and share similar asset-liability constraints. As such, helping both worlds share best practices is a major and long overdue step forward.”

”Respective frameworks of the two companies are very complementary, with Finlight adding significant depth to the portfolio construction and optimisation field, while LINKS is providing the real-world supply-chain-based scenario analysis and stress testing. The beneficiaries are the users who will get a one-stop-shop in terms of an innovative toolkit that will provide unparalleled forward-looking decision-making support in these uncertain times,” commented Taron Ganjalyan, Managing Director of LINKS Analytics B.V.

About Finlight: Finlight is an end-to-end, peer-driven and highly secure asset management software for family offices, enabling time and cost-effective advanced asset aggregation, reporting and 360 degrees of data-driven portfolio insights. Finlight was launched in 2016 with the vision of providing family offices with a fully integrated solution that makes technology affordable to simplify manual operational processes and strengthen alignment among stakeholders.

About LINKS Analytics: LINKS Analytics provides data-driven asset pricing, allocation, stress testing and scenario analysis innovative frameworks and related assistance to pension funds and insurance companies in Europe, with combined client assets under management of over EUR 450 billion.

Contact information

Jean-Bernard Tanqueray
Finlight
+44 20 7097 1686
contact@finlight.com

Taron Ganjalyan
LINKS Analytics B.V.
+31 70 891 9282
info@linksanalytics.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LintonPharm Announces Authorization From China Health Authority to Proceed With a Global Phase 3 Trial Evaluating Catumaxomab in Advanced Gastric Cancer15.7.2020 23:30:00 EESTPress release

LintonPharm Co. Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T-cell engaging bispecific antibodies for cancer immunotherapy, today announced the China National Medical Products Administration (NMPA) authorized the company to proceed with a Phase III trial (clinicaltrials.gov: NCT04222114) for catumaxomab in patients with peritoneal carcinomatosis, a form of advanced gastric cancer that has spread to the tissue that lines the abdominal cavity. The two-stage, multi-center, open-label, randomized, controlled registrational clinical trial will evaluate the safety and efficacy of an intraperitoneal infusion of the bi-specific antibody catumaxomab into the abdominal cavity in patients with peritoneal carcinomatosis. LintonPharm also recently received Clinical Trial Application (CTA) authorization for the same indication from the Taiwan Ministry of Health and Welfare (MOHW) and the Korea Ministry of Food and Drug Safety (MFDS). “We are excited to

Xerox Launches ConnectKey-Enabled AltaLink Digital Workplace Assistant15.7.2020 19:47:00 EESTPress release

Xerox announced its new Xerox AltaLink® C8100 and Xerox AltaLink B8100 Series multi-function printers (MFPs), that can better support today’s flexible work environment and help companies speed their digital transformation with access to the ConnectKey® ecosystem of apps. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200715005746/en/ The tablet-like user interface allows for easy, familiar interaction or the user can choose to print from their mobile devices. (Photo: Business Wire) In addition to its printing capabilities, the AltaLink 8100 series helps speed workplace digitization with ultra-fast scanning of up to 270 images per minute and Optical Character Recognition that allows clients to extract more value from information. Combined with ConnectKey apps, including connections to the most popular cloud solutions, these printers can support a key area of focus for businesses as they shift from physical to digital enterpri

Bureau Veritas Launches a New Solution to Improve Supply Chain Resilience15.7.2020 18:45:00 EESTPress release

Bureau Veritas , a world leader in testing, inspection and certification (TIC) services, is launching Supply-R, a solution designed to meet companies’ new challenges relating to supplier network reliability and ensuring business continuity in all circumstances. Organizations learned multiple lessons during the first half of 2020 on the resilience of global supply chains and their ability to face disruptions. There is an urgent need from many companies to reassess their supply chain risk, based on factual data from the field, to make sure that all elements are properly addressed, assessed and visible. Bruno Ferreyra, Executive Vice-President at Bureau Veritas, commented: "Economic globalization means supply chains include more suppliers and intermediaries than before, and they are scattered around the globe. This makes each step, process and stakeholder in the manufacturing chain harder to track. Our goal is to support businesses, mapping out their supply chains to give them complete co

VALBIOTIS Announces the First Patient First Visit in the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63 to Reduce Type 2 Diabetes Risk Factors15.7.2020 18:40:00 EESTPress release

Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME eligible) a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the First Patient First Visit in the international Phase II/III REVERSE-IT clinical study designed to assess TOTUM-63 for the reduction of Type 2 Diabetes metabolic risk factors. Murielle CAZAUBIEL, member of the Management Board and Director of Development and Medical Affairs at VALBIOTIS, comments: "The first visit of this first subject, a few days after obtaining both ANSM 1 approval and the favorable decision from the CPP 2 , marks the concrete launch of the REVERSE-IT study, the results of which are expected in mid-2022. We are right on schedule and are delighted to be able to enter the operational phase of this major study so quickly. We also welcome the enthusiasm and commitment of all the partner investigation centers." Dr Hans-Juergen WOERLE, Chief Scientific and Medical

Octapharma Reports Positive Data from octagam® Usage in Critically Ill COVID-19 Patients15.7.2020 18:04:00 EESTPress release

Topline results from a retrospective study in 93 critically ill COVID-19 patients have become available. The data shows that IVIG treatment reduces inflammation, which is associated with poor clinical outcomes and death, and points to an increase in survival, in critically ill COVID-19 patients, when compared to a control group. The study was conducted at the Istanbul University Hospital, Turkey, under the lead of Prof. Dr. Figen Esen. In critically ill COVID-19 patients, the cause of death often implicates an abnormal pulmonary immune response. This abnormal immune response is characterized by high levels of inflammatory markers, which are associated with poor clinical outcomes.1, 2 Acute respiratory distress syndrome (ARDS) and multiorgan failure are major causes of mortality in COVID-19 patients.3 High levels of pro-inflammatory cytokines and chemokines are part of a severe inflammatory response known as a “cytokine storm” which may cause multiple organ dysfunction and ARDS in criti

European Commission approves third nintedanib indication in pulmonary fibrosis115.7.2020 16:34:00 EESTPress release

Boehringer Ingelheim today announced that the European Commission (EC) has approved an additional indication for nintedanib in adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1 The approval comes after the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion in May 2020.3 The U.S. Food and Drug Administration (FDA), Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) recently approved nintedanib as the first treatment for the same patient population.4,5,6 Interstitial lung diseases encompass a large group of more than 200 disorders that may involve the threat of pulmonary fibrosis – an irreversible scarring of lung tissue that negatively impacts lung function.7 People living with fibrosing ILD can develop a progressive phenotype, leading to lung function decline, deterioration in quality of life and early mortality simila

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom